000162747 001__ 162747
000162747 005__ 20230915092405.0
000162747 0247_ $$2doi$$a10.1038/s41419-021-04058-z
000162747 0247_ $$2pmid$$apmid:34344867
000162747 0247_ $$2pmc$$apmc:PMC8328816
000162747 0247_ $$2altmetric$$aaltmetric:111019540
000162747 037__ $$aDZNE-2021-01403
000162747 041__ $$aEnglish
000162747 082__ $$a570
000162747 1001_ $$00000-0002-7351-5676$$aMauriello, Alessandro$$b0
000162747 245__ $$aThromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia.
000162747 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2021
000162747 3367_ $$2DRIVER$$aarticle
000162747 3367_ $$2DataCite$$aOutput Types/Journal article
000162747 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655732808_9506
000162747 3367_ $$2BibTeX$$aARTICLE
000162747 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162747 3367_ $$00$$2EndNote$$aJournal Article
000162747 500__ $$aCC BY
000162747 520__ $$aWhile vaccination is the single most effective intervention to drastically reduce severe disease and death following SARS-CoV-2 infection, as shown in UK and Israel, some serious concerns have been raised for an unusual adverse drug reaction (ADR), including vaccine-induced immune thrombotic thrombocytopenia (VITT) with concurrent low platelets as well as capillary leak syndrome. In fact, the overall safety of the vaccine is highlighted by the low frequency of ADR considering that in UK, by the early June, 40 million first doses and 29 million second doses have been injected; nonetheless, 390 thrombotic events, including 71 fatal events have been reported. Interestingly, the cases reported low platelet counts with the presence of anti-platelet factor-4 (PF4) antibodies, indicating an abnormal clotting reaction. Here, out of three referred cases, we report a post-vaccine clinical case of fatal thrombosis with postmortem examination and whole exome sequencing (WES) analysis, whose pathogenesis appeared associated to a preexisting condition of thrombocytopenia due to myelodysplasia.
000162747 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000162747 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162747 650_7 $$2NLM Chemicals$$aCOVID-19 Vaccines
000162747 650_7 $$0B5S3K2V0G8$$2NLM Chemicals$$aChAdOx1 COVID-19 vaccine
000162747 650_2 $$2MeSH$$aChAdOx1 nCoV-19
000162747 650_2 $$2MeSH$$aBone Marrow: pathology
000162747 650_2 $$2MeSH$$aCOVID-19: prevention & control
000162747 650_2 $$2MeSH$$aCOVID-19 Vaccines: adverse effects
000162747 650_2 $$2MeSH$$aFatal Outcome
000162747 650_2 $$2MeSH$$aFemale
000162747 650_2 $$2MeSH$$aHumans
000162747 650_2 $$2MeSH$$aLung: pathology
000162747 650_2 $$2MeSH$$aMiddle Aged
000162747 650_2 $$2MeSH$$aMyelodysplastic Syndromes: complications
000162747 650_2 $$2MeSH$$aMyelodysplastic Syndromes: diagnosis
000162747 650_2 $$2MeSH$$aMyelodysplastic Syndromes: pathology
000162747 650_2 $$2MeSH$$aSARS-CoV-2: immunology
000162747 650_2 $$2MeSH$$aThrombocytopenia: complications
000162747 650_2 $$2MeSH$$aThrombocytopenia: diagnosis
000162747 650_2 $$2MeSH$$aThrombocytopenia: pathology
000162747 650_2 $$2MeSH$$aThromboembolism: etiology
000162747 7001_ $$00000-0003-0585-1309$$aScimeca, Manuel$$b1
000162747 7001_ $$00000-0003-0739-325X$$aAmelio, Ivano$$b2
000162747 7001_ $$00000-0001-7971-0715$$aMassoud, Renato$$b3
000162747 7001_ $$00000-0002-5671-9220$$aNovelli, Antonio$$b4
000162747 7001_ $$00000-0001-8574-337X$$aDi Lorenzo, Francesca$$b5
000162747 7001_ $$00000-0002-8684-4831$$aFinocchiaro, Susanna$$b6
000162747 7001_ $$00000-0002-5793-9727$$aCimino, Carolina$$b7
000162747 7001_ $$00000-0002-5365-7167$$aTelesca, Rossana$$b8
000162747 7001_ $$00000-0001-6041-4166$$aChiocchi, Marcello$$b9
000162747 7001_ $$00000-0001-8094-2214$$aSun, Qiang$$b10
000162747 7001_ $$00000-0002-2571-9367$$aWang, Ying$$b11
000162747 7001_ $$00000-0001-8964-319X$$aShi, Yufang$$b12
000162747 7001_ $$00000-0002-7781-602X$$aNovelli, Giuseppe$$b13
000162747 7001_ $$0P:(DE-2719)9001390$$aMelino, Gerry$$b14$$eLast author$$udzne
000162747 773__ $$0PERI:(DE-600)2541626-1$$a10.1038/s41419-021-04058-z$$gVol. 12, no. 8, p. 762$$n8$$p762$$tCell death & disease$$v12$$x2041-4889$$y2021
000162747 8564_ $$uhttps://pub.dzne.de/record/162747/files/DZNE-2021-01403.pdf$$yOpenAccess
000162747 8564_ $$uhttps://pub.dzne.de/record/162747/files/DZNE-2021-01403.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162747 909CO $$ooai:pub.dzne.de:162747$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162747 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001390$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000162747 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000162747 9141_ $$y2021
000162747 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162747 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000162747 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL DEATH DIS : 2021$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:53Z
000162747 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:53Z
000162747 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-14T16:18:53Z
000162747 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000162747 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL DEATH DIS : 2021$$d2022-11-17
000162747 9201_ $$0I:(DE-2719)5000018$$kAG Nicotera$$lSynaptic Connectivity and Neurodegeneration$$x0
000162747 980__ $$ajournal
000162747 980__ $$aVDB
000162747 980__ $$aUNRESTRICTED
000162747 980__ $$aI:(DE-2719)5000018
000162747 9801_ $$aFullTexts